Table 1
Demographic and clinical characteristics of patients with osteoarthritis of the knee or hip at baseline according to rheumatologist groups randomised by intervention
| Patient characteristics | Rheumatologist intervention groups | |||||||
|---|---|---|---|---|---|---|---|---|
| Standardised tools (n = 782) | Exercise (n = 735) | Standardised tools + exercise (n = 680) | Usual care (n = 760) | |||||
| Hip (n = 197) | Knee (n = 585) | Hip (n = 185) | Knee (n = 550) | Hip (n = 167) | Knee (n = 513) | Hip (n = 192) | Knee (n = 568) | |
*For patients with knee osteoarthritis, with SD corrected according to the inflation coefficient  is the mean size of cluster (2.6) and ρ is the intra-class correlation coefficient (ICC), which was 0.095 for age, 0.060 for BMI, 0.061 for duration of symptoms, 0.185 for pain intensity, 0.213 for WOMAC, and 0.177 for patient global assessment. | ||||||||
| NSAID, non-steroidal anti-inflammatory drug; SYSADOA, systematic slow acting drug for osteoarthritis; IA, intra-articular; VAS, visual analogue scale. | ||||||||
| Age mean (SD), years | 64.1 (10.8) | 68.1 (10.5) | 63.8 (9.9) | 68.0 (9.9) | 62.8 (8.9) | 66.5 (10.5) | 65.1 (10.7) | 68.1 (10.2) |
| Age >75 years, no. (%) | 34 (17.4) | 158 (27.1) | 23 (12.5) | 131 (23.9) | 17 (10.2) | 104 (20.3) | 32 (16.7) | 150 (26.4) |
| Male, no. (%) | 75 (38.1) | 159 (27.2) | 72 (38.9) | 143 (26.0) | 65 (38.9) | 160 (31.2) | 69 (35.9) | 140 (24.6) |
| BMI mean (SD)* | 26.3 (3.9) | 28.2 (5.1) | 26.0 (3.9) | 28.3 (5.4) | 26.2 (4.3) | 28.1 (4.9) | 26.4 (4.3) | 28.4 (5.2) |
| Mean duration of symptoms (SD), (months) | 53.8 (62.0) | 76.5 (83.2) | 59.9 (68.4) | 72.3 (73.3) | 53.4 (63.7) | 76.9 (80.2) | 51.3 (54.4) | 72.1 (77.9) |
| Mean (SD) VAS pain (0–100)* | 54.4 (16.8) | 56.8 (17.2) | 57.7 (15.8) | 59.7 (18.2) | 53.0 (14.1) | 54.6 (16.8) | 57.2 (16.4) | 60.4 (18.3) |
| Mean WOMAC function score (0–100)* | 45.5 (15.6) | 44.5 (18.7) | 44.9 (15.7) | 45.4 (18.8) | 41.7 (17.0) | 43.1 (18.3) | 45.6 (17.8) | 45.7 (18.8) |
| Patient global assessment (SD) (0–100)* | 56.3 (18.5) | 57.3 (19.8) | 60.8 (18.8) | 61.0 (21.1) | 55.3 (17.3) | 56.6 (19.4) | 60.7 (18.6) | 61.3 (19.9) |
| Radiological grade (Kellgren and Lawrence) | ||||||||
| II | 35 (17.8) | 85 (14.5) | 40 (21.6) | 86 (15.7) | 33 (19.8) | 85 (16.6) | 36 (18.7) | 93 (16.4) |
| III | 105 (53.3) | 262 (44.8) | 100 (54.1) | 261 (47.5) | 83 (49.7) | 227 (44.2) | 104 (54.2) | 258 (45.4) |
| IV | 57 (28.9) | 238 (40.7) | 45 (24.3) | 202 (36.8) | 51 (30.5) | 201 (39.2) | 52 (27.1) | 217 (38.2) |
| Osteoarthrtitis in other joints, no (%) | 176 (93.12) | 550 (94.83) | 162 (89.50) | 504 (92.99) | 150 (91.46) | 476 (93.52) | 166 (89.25) | 520 (93.86) |
| Prior treatment | ||||||||
| NSAIDs, no. (%) | 131 (66.5) | 354 (60.5) | 115 (62.2) | 354 (64.3) | 123 (73.6) | 349 (68.1) | 125 (65.1) | 361 (53.6) |
| SYSADOA, no. (%) | 73 (37.1) | 237 (40.5) | 78 (42.2) | 243 (44.2) | 74 (44.3) | 221 (43.1) | 75 (39.1) | 221 (38.9) |
| IA treatment, no. (%) | 10 (5.1) | 235 (40.2) | 3 (1.6) | 214 (38.9) | 1 (0.6) | 186 (36.3) | 9 (4.7) | 208 (36.6) |